For more than 40 years, Jon Gockerman, MD, has shaped how oncology clinical trials are designed, implemented and evaluated, including solid tumor and hematology/oncology clinical research. As a Senior Medical Director at IQVIA Biotech, Dr. Gockerman brings valuable medical and research expertise to oncology programs. He developed a keen interest in oncology as a fellow at Duke University and understands how to communicate effectively with patients, key opinion leaders and business professionals. As such, Dr. Gockerman plays an integral role in overseeing the analysis of preclinical and clinical data along with the development of training materials and informed consent forms at IQVIA Biotech.
In addition to being well-versed in the complexities of solid tumor oncology trials, Dr. Gockerman brings a wealth of knowledge around hematologic oncology malignancies, enabling him to provide expert input into study protocol design, determination of inclusion/exclusion criteria, and endpoints selection. The impact of his work has allowed IQVIA Biotech to deliver successful hematologic oncology trials and build thought leadership in this challenging area of drug development.
Prior to joining IQVIA Biotech, Dr. Gockerman served as a Professor of Medicine at Duke University Medical Center. During his 18-year tenure, he received the “America’s Top Doctors for Cancer” award from 2001-2011. He earned his medical degree from the University of Chicago, and later completed his internal medicine and fellowship training in hematology/oncology at Duke University. Working closely with the Phase I group at Duke University Medical Center, Dr. Gockerman completed new drug discovery studies, including the pazopanib study, which was later approved for the treatment of renal cell carcinoma and soft tissue sarcoma by the U.S. Food and Drug Administration. For three decades, Dr. Jon Gockerman has devoted his time to Phase I, II and III leukemia, lymphoma and myeloma clinical trials, where he has developed a deep understanding of patient needs and clinical trial requirements in this field.
Dr. Gockerman has authored more than 100 peer-reviewed publications, most of which address clinical research or clinical laboratory questions. He is an active member of the American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH) and American Society for the Advancement of Science (AAAS).
As a pioneer in advancing oncology clinical research and an awarding-winning physician, Dr. Gockerman has had a meaningful impact on countless lives and brings immeasurable value to IQVIA Biotech’s oncology team. He believes staying up to date in the field of medicine allows for a better appreciation of advances that can be applied to hematology and oncology.
Having a team with expertise in your therapeutic area is crucial to the success of your clinical development program. Contact us to learn how our dedicated oncology team can support your next study.